BC Week In Review | Oct 10, 2016
Company News

Arena, Eisai sales and marketing update

Eisai launched Belviq XR lorcaserin extended release for chronic weight management. The wholesale acquisition cost (WAC) for a 20 mg tablet is $8.04. Belviq is approved in the U.S. as an adjunct to diet and...
BC Week In Review | Jul 25, 2016
Clinical News

Belviq XR lorcaserin extended release regulatory update

Eisai and Arena said FDA approved an NDA for once-daily Belviq XR lorcaserin extended release for chronic weight management. The companies expect the drug to be available this fall. The approval triggered a $10 million...
BC Week In Review | Dec 7, 2015
Clinical News

Belviq XR lorcaserin extended release regulatory update

Eisai and Arena said FDA accepted an NDA for once-daily Belviq XR lorcaserin extended release for chronic weight management. The partners did not disclose the PDUFA date. The product is an extended-release formulation of twice-daily...
Items per page:
1 - 3 of 3